Drug intelligence / Profile preview

pHIS-HIV-AE + rFPV-HIV-AE

Development stage: Discontinued
Lead developer: The Kirby Institute
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

pHIS-HIV-AE + rFPV-HIV-AE is a combination HIV vaccine regimen developed as a prime-boost strategy for the prevention of HIV-1 infection. The regimen consists of two components: - **pHIS-HIV-AE** is a DNA vaccine that delivers genes from the AE clade of HIV-1, intended to prime the immune system. - **rFPV-HIV-AE** is a recombinant fowlpox virus vector vaccine delivering the same AE clade HIV-1 genes, used as a booster following priming with pHIS-HIV-AE. The mechanism involves immunostimulation by presenting HIV antigens to elicit both cellular and humoral immune responses against HIV. This approach aims to enhance immunogenicity compared to single-modality vaccination. The combination was evaluated in clinical trials for safety and immunogenicity in healthy adults at risk for HIV infection but development has been discontinued after early-phase studies[1][7].

Other names: HIV-1 DNA prime, recombinant fowlpox virus boostDNA/fowlpox HIV vaccinepHIS-HIV-AE/rFPV-HIV-AE

Targets

gp41 (Human immunodeficiency virus type 1 glycoprotein 41)

Beyond the preview

Go deeper on pHIS-HIV-AE + rFPV-HIV-AE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pHIS-HIV-AE + rFPV-HIV-AE.

Explore the full profile